By suppressing cell growth and invasion via blockage of MAPK and transforming growth factorβ (TGFβ)/SMADs signaling respectively, one study demonstrated PPARγ agonists as a promising therapy option for NSCLC [179]. Here, PPARG is linked to non-small cell lung carcinoma.